Literatur

1. Madhok R, et al. Serum interleukin 6 levels in rheumatoid
   arthritis: correlations with clinical and laboratory indices of disease activity. Ann Rheum Dis 1993; 52:232–234.

2. RoACTEMRA® (tocilizumab) Summary of Product Characteristics. Roche Registration Limited. December 2010.

3. Jones G, et al. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: The AMBITION study. Ann Rheum Dis2010; 69:88–96.

4. Smolen JS, et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet 2008; 371:987–997.

5. Genovese MC, et al. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: The tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. Arthritis Rheum 2008; 58:2968–2980.

6. Emery P, et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-TNF biologics: results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis 2008; 67:1516–1523.